Kind Pharmaceutical

Calculating rank

USPTO Granted Patents = 6

CIPO Patents = 1

EPO Patents = 2

Forward Citations = 4

Loading Chart...

7 inventors (with patents filed for the assignee):

Dong Liu (6 out of 9 patents)

Dongdong Chen (4 out of 15 patents)

Biao Deng (4 out of 4 patents)

4. Xiangyun Tu (4 out of 4 patents)

5. Zinan Fang (4 out of 4 patents)

6. Haohao Wu (4 out of 4 patents)

7. Danyan Gu (4 out of 4 patents)

8. Dong Liu (0 patent)

6 patents: Sort by Forward Citations

1. 11970495 - Indolizine derivatives and their application in medicine (2024-04-30),

2. 11945817 - Indolizine derivatives and their application in medicine (2024-04-02),

3. 11718615 - Heterocyclic compounds and their application in medicine (2023-08-08),

4. 11655249 - Indolizine derivatives and their application in medicine (2023-05-23),

5. 11236088 - Heterocyclic compounds and their application in medicine (2022-02-01),

6. 11021478 - Indolizine derivatives and their application in medicine (2021-06-01),

Company Overview

Kind Pharmaceutical is a leading pharmaceutical company that specializes in developing innovative and high-quality medications. With a focus on patient care and medical advancements, Kind Pharmaceutical is dedicated to improving the lives of individuals through its cutting-edge drugs and treatments.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

6 Patents

#117 in Hangzhou

#4,489 in China

Hangzhou, China

Kind Pharmaceutical

Forward Citations = 4

7 inventors:

Dong Liu (6 out of 9 patents)

Dongdong Chen (4 out of 15 patents)

Biao Deng (4 out of 4 patents)

4. Xiangyun Tu (4 out of 4 patents)

5. Zinan Fang (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Kind Pharmaceutical. Retrieved from https://idiyas.com/company/kind-pharmaceutical

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

2 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]